NasdaqGM:VCYTBiotechs
Veracyte (VCYT) Rises 10.4% After Lifting 2025 Revenue Outlook and Reporting Strong Q2 Sales
Earlier this month, Veracyte announced its second quarter 2025 results, with revenue rising to US$130.16 million from US$114.43 million a year earlier, but swinging from net income to a small net loss; the company also raised its revenue guidance for the full year to a new range of US$496 million to US$504 million and increased its expected testing revenue growth.
The updated guidance, alongside strong first-half revenue figures, underscores management's increased confidence in higher demand...